Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results

References

• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32. doi: 10.1182/blood-2014-05-577189.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood. 2015;125(1):33–39. doi: 10.1182/blood-2014-05-575092.
   PubMed Web of Science ®Google Scholar
• Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125(1):40–47. doi: 10.1182/blood-2014-04-516815.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. About non-Hodgkin lymphoma. 2022.
   Google Scholar
• Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: r -CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366–378. doi: 10.1182/asheducation-2016.1.366.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462–4469. doi: 10.1200/JCO.2012.41.9416.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi: 10.1182/blood-2017-03-769620.
   PubMed Web of Science ®Google Scholar
• Vitale C, Strati P. CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10:849. doi: 10.3389/fonc.2020.00849.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. YESCARTA® (axicabtagene ciloleucel) suspension for intravenous infusion. 2017.
   Google Scholar
• Food and Drug Administration. KYMRIAH® (tisagenlecleucel) suspension for intravenous infusion. 2017.
   Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi: 10.1056/NEJMoa1707447.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi: 10.1056/NEJMoa1804980.
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Jansen JP, Lin VW, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2020;6(9):1581–1588. doi: 10.1016/j.bbmt.2020.06.008.
   Google Scholar
• Liu R, Oluwole OO, Diakite I, et al. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24(1):458–468. doi: 10.1080/13696998.2021.1901721.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. doi: 10.1016/s1470-2045(21)00375-2.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Jacobson CA, Ghobadi A, et al. 5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. 2023;141(19):2307–2315. doi: 10.1182/blood.2022018893.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. ICER's reference case for economic evaluations: principles and rationale. 2020.
   Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42. doi: 10.1016/S1470-2045(18)30864-7.
   PubMed Web of Science ®Google Scholar
• Lambert PC, Thompson JR, Weston CL, et al. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007;8(3):576–594. doi: 10.1093/biostatistics/kxl030.
   PubMed Web of Science ®Google Scholar
• Lambert PC. Modeling of the cure fraction in survival studies. Stata J. 2007;7(3):351–375. doi: 10.1177/1536867X0700700304.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. NCHS – National vital statistics system. mortality: life tables US 2020. 2020 [cited 2020 Nov]. https://ftpcdcgov/pub/Health_Statistics/NCHS/Publications/NVSR/67_07/(Table02 males, Table 03 females)
   Google Scholar
• Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245. doi: 10.1080/13696998.2018.1529674.
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Liu R, Diakite I, et al. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. J Med Econ. 2022;25(1):541–551. doi: 10.1080/13696998.2022.2065787.
   PubMed Web of Science ®Google Scholar
• Yang H, Hao Y, Chai X, et al. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective. J Med Econ. 2020;23(9):1016–1024. doi: 10.1080/13696998.2020.1769109.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Tisagenlecleucel for diffuse large B-cell lymphoma: economic review report. Optimal Use Report. 2019 [cited 2019 Oct 25]. https://www.cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-economic-report-DLBCL-jan2019.pdf.
   Google Scholar
• Lin VW, Jiang Y, Chuang LH, et al. Health utilities for patients with relapsed or refractory large B-cell lymphoma (R/R-LBCL): ad hoc analysis from an axicabtagene ciloleucel (axi-cel) safety management study. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation; Lisbon, Portugal. 2018.
   Google Scholar
• Chen Q, Staton AD, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(7):1700–1709. doi: 10.1080/10428194.2017.1390230.
   PubMed Web of Science ®Google Scholar
• IBM Micromedex(a). RED BOOK ® online. 2023 [cited 2023 Nov 3]. www.ibm.com/products/micromedex-red-book.
   Google Scholar
• IBM Micromedex(b). RED BOOK® online. 2022 [cited 2022 Oct 12]. www.ibm.com/products/micromedex-red-book.
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule. 2022 [cited 2022 Nov 28]. https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx.
   Google Scholar
• CMS – Centers for Medicare & Medicaid Services. CMS medicare fee schedule. 2022. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/FeeScheduleGenInfo/index.html.
   Google Scholar
• Bureau of Labor Statistics. Consumer price index. Medical care component. 2022 [cited 2022 Nov 28]. https://data.bls.gov/timeseries/CUUR0000SAM?output_view=data.
   Google Scholar
• IBM Micromedex(c). RED BOOK® online. 2019 [cited 2019 Dec 3]. www.ibm.com/products/micromedex-red-book.
   Google Scholar
• Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10(7):366–374.
   PubMed Web of Science ®Google Scholar
• Wakase S, Teshima T, Zhang J, et al. Cost effectiveness analysis of tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma in Japan. Transplant Cell Ther. 2021;27(6):506 e1-506–e10. doi: 10.1016/j.jtct.2021.03.005.
   Google Scholar
• Agency for Healthcare Research and Quality. Healthcare cost and utilization project (HCUP) 2018 [cited 2022 Nov 28]. https://hcupnet.ahrq.gov.
   Google Scholar
• Gershengorn HB, Garland A, Gong MN. Patterns of daily costs differ for medical and surgical intensive care unit patients. Ann Am Thorac Soc. 2015;12(12):1831–1836. doi: 10.1513/AnnalsATS.201506-366BC.
   PubMed Web of Science ®Google Scholar
• Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol. 2015;33(13):1467–1474. doi: 10.1200/JCO.2014.58.5729.
   PubMed Web of Science ®Google Scholar
• Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leuk Lymphoma. 2006;47(8):1535–1544. doi: 10.1080/10428190600573325.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Press OU; 2006.
   Google Scholar
• Institute for Clinical and Economic Review. 2020–2023 value assessment framework. 2020.
   Google Scholar
• Bastos-Oreiro M, de Las Heras A, Presa M, et al. Cost-Effectiveness analysis of axicabtagene ciloleucel vs. Tisagenlecleucel for the management of relapsed/refractory diffuse large B-cell lymphoma in Spain. Cancers. 2022;14(3):538. doi: 10.3390/cancers14030538.
   PubMed Web of Science ®Google Scholar
• Brighton N, Lovato E, Castaigne JG. Assessing the cost-effectiveness of axicabtagene ciloleucel compared with other CAR T-cell therapies in the treatment of diffuse large B-cell lymphoma in the UK. Value Health. 2022;25(12): S141. doi: 10.1016/j.jval.2022.09.683.
   Web of Science ®Google Scholar
• Brighton N, Zang A, Castaigne JG. Cost-effectiveness of axicabtagene ciloleucel versus other CAR T-cell therapies in the treatment of diffuse large B-cell lymphoma in France. Value Health. 2022;25(12):S81. doi: 10.1016/j.jval.2022.09.398.
   Web of Science ®Google Scholar
• Jacobson CA, Munoz J, Sun F, et al. Effectiveness and safety of axicabtagene-ciloleucel and tisagenlecleucel for large B-cell lymphoma in the real-world setting: a systematic review and meta-analysis. Poster presented at EBMT-EHA 5th European CAR T-cell meeting February 2023. 2023.
   Google Scholar
• Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145–2154. doi: 10.1038/s41591-022-01969-y.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016 [cited 2023 Dec]. http://wwwnicedsuorguk.
   Google Scholar
• National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. NICE TA872. 2023 [cited 2023 Dec]. https://wwwniceorguk/guidance/ta872/resources/axicabtagene-ciloleucel-for-treating-diffuse-large-bcell-lymphoma-and-primary-mediastinal-large-bcell-lymphoma-after-2-or-more-systemic-therapies-pdf-82613669792965
   Google Scholar
• Parker C, Liu FF, Deger KA, et al. Cost-Effectiveness of lisocabtagene maraleucel versus axicabtagene ciloleucel and tisagenlecleucel in the third-line or later treatment setting for relapsed or refractory large B-cell lymphoma in the United States. Adv Ther. 2023;40(5):2355–2374. doi: 10.1007/s12325-023-02444-x.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Axicabtagene ciloleucel for large B-cell lymphoma: economic review report. CADTH optimal use report: vol 9, no 1d. 2019 [cited 2023 Dec]. https://www.cadth.ca/sites/default/files/pdf/car-t/ct0002-axicabtagene-ciloleucel-economic-report-redacted.pdf
   Google Scholar
• Food and Drug Administration. BREYANZI®(lisocabtagene maraleucel) suspension for intravenous infusion. 2022.
   Google Scholar
• Maloney DG, Kuruvilla J, Liu FF, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. J Hematol Oncol. 2021;14(1):140. doi: 10.1186/s13045-021-01144-9.
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Chen JMH, Chan K, et al. ABCL-289: matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more prior lines of therapy. Clin Lymphoma Myeloma Leuk. 2021;21:S388. doi: 10.1016/S2152-2650(21)01882-6.
   Web of Science ®Google Scholar
• Locke FL, Ray MD, Bradford R, et al. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel in 3L + relapsed/refractory large b-cell lymphoma in the United States: utilizing real-world evidence of CAR T-cell therapies. Presented at ISPOR Europe 2023. Copenhagen, Denmark. 2023.
   Google Scholar